Perimenopause Symptoms in Singapore: Why It Gets Missed

Perimenopause is the transition into menopause, and it commonly begins in a woman’s early forties — sometimes late thirties. At Advantage Medical Group we see it presenting differently in Singapore than the Western textbooks describe. Hot flushes are not the leading complaint. Muscle aches, joint pain, disrupted sleep and brain fog are.

That difference matters, because it is why perimenopause goes unrecognised. A woman who is sleeping badly, aching, and losing words mid-sentence does not think of perimenopause — and often neither does anyone around her. She is told she is stressed, or busy, or that this is simply what her forties feel like.

Diagnosis is clinical, not a single blood test. Hormones fluctuate through perimenopause, so one FSH, LH or oestradiol reading can look entirely normal in a woman who is clearly transitioning. We run a full hormonal panel alongside thyroid function, iron studies and insulin, because thyroid disease, anaemia and insulin resistance all produce similar symptoms.

Where symptoms warrant it and the patient is suitable, hormone therapy — HRT — is one of the options we discuss. That conversation changed in November 2025, when the FDA removed the black box warnings it had placed on hormone therapy two decades earlier. Those warnings came from a 2002 trial whose findings were applied far more broadly than the data supported. The drugs did not change. The reading of the evidence did.

We see patients for this at our Bukit Timah, Marine Parade and Jurong West clinics. Assessment can sit within a standard health screening, or within the VITAL Screen for a fuller picture of cardiovascular, metabolic and bone health during the transition.

What the Singapore data actually shows

This is not a clinical impression. The Integrated Women’s Health Programme followed 1,054 midlife Singaporean women and found the leading menopausal symptoms to be joint and muscle discomfort, sleep problems, and physical and mental exhaustion. Hot flushes ranked fifth. An earlier community study of 495 women found hot flushes in 17.6% and night sweats in 8.9%, far below the rates reported in Caucasian cohorts.

So the transition gets attributed to something else. Work stress. Young children. Poor sleep hygiene. Age. Each explanation is plausible on its own, and each costs the patient years of symptoms that did not need to continue.

The cognitive change is the one women find hardest to raise, because it sounds trivial said aloud. Losing words mid-sentence. Re-reading the same email three times. Walking into a room without knowing why. It is not trivial, and as the next section shows, it is measurable.

Why a normal blood test does not settle it

Ovarian function does not decline smoothly through the transition. It fluctuates, sometimes considerably, cycle to cycle. FSH may be raised one month and entirely normal the next. Oestradiol can swing from low to high within a single cycle. A blood test taken on the wrong day in a woman who is unmistakably perimenopausal will read as normal.

So we treat the patient, not the number. Blood work supports the clinical picture and, more importantly, excludes the other conditions that produce the same symptoms.

• Hormonal panel — FSH, LH, oestradiol, progesterone
• Thyroid function — TSH, free T4. Hypothyroidism produces fatigue, weight gain, low mood and cognitive slowing, and is common in women of this age.
• Iron studies — ferritin, iron, transferrin. Perimenopausal periods are often heavier, and iron deficiency causes exhaustion and poor concentration well before it causes anaemia.
• HOMA-IR with fasting insulin and glucose — insulin resistance frequently emerges through this transition and drives weight gain, fatigue and poor sleep in its own right. We cover this in more detail in our article on insulin resistance.

If a woman has been told her thyroid and iron are normal and she still feels this way, that is not the end of the assessment. It is the beginning of a different one.

This is not only about the ovaries

The clinical framing that helps most patients is that perimenopause is a systemic transition, not a reproductive event that happens in isolation.

Cardiovascular

Oestrogen upregulates hepatic LDL receptors, which clear LDL from the bloodstream. As oestrogen falls, LDL rises — in women who have changed nothing about their diet or exercise. A patient in her late forties whose cholesterol has been stable for a decade gets a corporate screening result she cannot account for, and the transition itself is the explanation. This is also the point at which women’s cardiovascular risk begins converging with men’s, and where markers like ApoB and lipoprotein(a) give a more precise picture than LDL alone.

Bone

Bone loss does not start at menopause. SWAN data show bone mineral density begins declining roughly one year before the final menstrual period and continues for about three years after. The rapid-loss window opens while a woman is still menstruating and has no reason to think anything has changed — which is the argument for building reserve in your forties rather than your sixties.

Metabolic

Insulin sensitivity commonly declines through the transition, and fat distribution shifts centrally — including visceral fat, which is metabolically active and carries risk that BMI does not capture. Women often describe this precisely: same diet, same activity, different body.

Cognitive

Brain fog is not a figure of speech. Objective testing across the menopausal transition shows measurable changes in verbal memory and processing speed, with recovery in many women afterwards. Whether hormone therapy protects long-term cognition is genuinely open — the evidence is not strong enough to prescribe HRT for that reason alone, and we do not.

What changed with HRT in 2025

Three problems with the 2002 warnings became clear over time. WHI participants averaged 63 years of age, more than a decade past menopause onset — and the risk profile of starting at 63 is not the risk profile of starting at 50. The formulations studied are not the ones in common use today. And the findings were applied as a class effect across every product and every route, including low-dose vaginal preparations with minimal systemic absorption.

On 10 November 2025, after an expert advisory panel and a public comment period, the FDA moved to remove the warnings relating to cardiovascular disease, breast cancer, stroke and probable dementia. Updated labelling emphasises timing: benefit is greatest when therapy starts within ten years of menopause onset, or before age 60.

One warning was not removed: endometrial cancer, on systemic oestrogen-only products in women with a uterus. That is why oestrogen is prescribed with a progestogen in women who have not had a hysterectomy.

On breast cancer, the largest synthesis available — 58 pooled studies, 143,887 women with breast cancer and 424,972 without — found that five years of combined oestrogen-progestogen therapy started at 50 raises the 20-year risk between ages 50 and 69 from 6.3% to 8.3%. That is one additional case for every 50 women treated. Oestrogen-only therapy, for women who have had a hysterectomy, carries a substantially smaller increase, around one in 200.

That is a real increase and we do not minimise it.

Two things belong alongside it. Those baselines are Western: Singapore’s incidence is around 62 per 100,000 women against roughly 90 in the United States, so the absolute numbers here are likely smaller — though the relative effect has not been measured separately in Asian populations, and Singapore’s incidence has tripled since the 1970s. That is an argument for staying screened, not against treatment.

And remaining symptomatic is not a neutral alternative. Sleep deprivation, accelerated bone loss and untreated cardiovascular risk carry their own costs.

Route matters. Patches and gels bypass first-pass hepatic metabolism, and the clot risk differs sharply: in the ESTHER study, odds of venous thromboembolism against non-users were 4.2 for oral oestrogen and 0.9 for transdermal. Where either would work, we prefer transdermal.

“I’ve had breast cysts — can I still consider HRT?”

This question stops a lot of women before they ask it. It is worth answering directly.

Breast cysts and benign mammogram findings are not absolute contraindications to hormone therapy. Neither is dense breast tissue, nor a family history of breast cancer in isolation. They make the discussion more careful. They do not close it.

The absolute contraindications are narrower than most people assume:

• Active oestrogen-receptor-positive breast cancer
• Active venous thromboembolism
• Undiagnosed vaginal bleeding

Everything outside that list is a conversation about individual risk, individual benefit, and how closely you want to be monitored. Women on HRT under our care have annual mammograms as part of routine follow-up.

The door is not closed. The conversation is what matters.

The supplement problem

A pattern we see often enough to name: a woman spending SGD 150–200 a month on magnesium, melatonin, evening primrose oil, black cohosh and collagen, still not sleeping, still symptomatic.

Most of these have little evidence behind them for what they are being taken for. Hormone therapy typically costs under SGD 100 a month and treats the underlying change rather than working around it.

Where there is a reason for a supplement we will say so — vitamin D deficiency is genuine and common here. But spending more than the cost of treatment on things that are not treatment is a poor trade, and it usually happens because nobody had the conversation about what else was available.

What we actually do

Symptoms first

The history is the most important part of the assessment. We treat the patient, not the number.

Full workup

Hormonal panel, thyroid, iron studies, HOMA-IR — because these symptoms are non-specific and we need to exclude the alternatives before attributing everything to perimenopause.

Risk assessment

Personal and family history, cancer history, breast imaging status, clot history, cardiovascular risk.

If HRT is appropriate

We discuss the evidence, the options, the route, and the monitoring plan. The patient decides. Some women choose to proceed, some choose to wait, some choose not to. All three are reasonable.

Monitoring

More frequent review initially while dose and formulation settle, then every three to six months at steady state, with annual mammograms. Preparations used in perimenopause differ from those used after menopause is established, and treatment is adjusted when the transition is confirmed.

If you are in your forties and not symptomatic yet

Four things are worth doing before the transition rather than during it.

• Check vitamin D and correct it. Deficiency is common in Singapore despite the climate — most of us work indoors.
• Resistance training. Bone and muscle are built more easily before the transition than rebuilt after it. This is the single highest-value intervention on the list.
• Protein. Most Asian dietary patterns under-deliver protein relative to what is needed to maintain muscle mass through midlife.
• Consider creatine, 5 g daily — alongside resistance training, not instead of it. Meta-analyses in postmenopausal women show small gains in lean mass and strength when the two are combined. Safety at this dose is well documented.

We cover muscle maintenance in more detail in our article on sarcopenia, and cardiorespiratory fitness in VO₂ max.